Dr. Guitera on the RADICAL Trial for Melanoma

Pascale Guitera, MD
Published: Wednesday, Oct 25, 2017



Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, University of Sydney, discusses the RADICAL trial of patients with melanoma.

The phase III multicenter RADICAL trial is investigating patients with lentigo maligna melanoma. Lengito maligna is an early stage of melanoma that is generally found in elderly patients and is difficult to operate on.

In the trial, patients were randomized to radiotherapy or imiquimod to determine the efficacy of these treatments. The primary endpoint is treatment failure at 6 months that is biopsy proven. Secondary endpoints include treatment failure at 12 months and 24 months.
 


Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, University of Sydney, discusses the RADICAL trial of patients with melanoma.

The phase III multicenter RADICAL trial is investigating patients with lentigo maligna melanoma. Lengito maligna is an early stage of melanoma that is generally found in elderly patients and is difficult to operate on.

In the trial, patients were randomized to radiotherapy or imiquimod to determine the efficacy of these treatments. The primary endpoint is treatment failure at 6 months that is biopsy proven. Secondary endpoints include treatment failure at 12 months and 24 months.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x